Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWRNYSE:BHCNASDAQ:HRMYNASDAQ:LCAP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$17.17+1.2%$13.90$9.57▼$30.41$2.37B0.961.52 million shs58,020 shsBHCBausch Health Companies$5.05-1.1%$4.82$3.96▼$9.85$1.87B0.282.55 million shs82,814 shsHRMYHarmony Biosciences$36.09+0.7%$31.92$26.47▼$41.61$2.06B0.87614,573 shs31,381 shsLCAPLionheart Acquisition Co. II$26.23+0.5%$10.38$8.94▼$11.70$483.96M0.08102,067 shs1,624 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+2.41%+2.17%+30.44%+7.61%-30.76%BHCBausch Health Companies+4.20%+11.03%+11.76%-25.06%-19.54%HRMYHarmony Biosciences+1.21%+1.53%+5.29%+6.70%+19.82%LCAPLionheart Acquisition Co. II-0.16%+0.73%+4.72%+1,374.43%+3,633.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.7317 of 5 stars3.42.00.03.42.42.50.0BHCBausch Health Companies4.5787 of 5 stars2.95.00.04.02.51.71.9HRMYHarmony Biosciences4.9537 of 5 stars4.64.00.00.03.43.34.4LCAPLionheart Acquisition Co. IIN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.75Moderate Buy$43.71154.58% UpsideBHCBausch Health Companies 1.86Reduce$7.4247.01% UpsideHRMYHarmony Biosciences 3.11Buy$53.0046.88% UpsideLCAPLionheart Acquisition Co. II 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LCAP, ARWR, HRMY, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/13/2025ARWRArrowhead PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.005/13/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.005/2/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.004/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/8/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$545.21M4.35N/AN/A$1.54 per share11.15BHCBausch Health Companies$9.73B0.19$5.37 per share0.94($0.89) per share-5.67HRMYHarmony Biosciences$744.85M2.78$2.70 per share13.38$7.97 per share4.53LCAPLionheart Acquisition Co. IIN/AN/A$1.27 per share20.64($2.85) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/AN/AN/A-236.60%-64.09%8/6/2025 (Estimated)BHCBausch Health Companies-$46M-$0.11N/A1.080.37-0.48%-577.82%5.24%7/30/2025 (Estimated)HRMYHarmony Biosciences$128.85M$2.6217.0411.600.4717.98%23.16%14.24%8/5/2025 (Estimated)LCAPLionheart Acquisition Co. II$3.21MN/A0.00∞N/AN/A-44.30%1.39%N/ALatest LCAP, ARWR, HRMY, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CompaniesN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ALCAPLionheart Acquisition Co. IIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals7.276.096.09BHCBausch Health CompaniesN/A0.860.62HRMYHarmony Biosciences0.283.243.20LCAPLionheart Acquisition Co. IIN/A0.050.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%BHCBausch Health Companies78.65%HRMYHarmony Biosciences86.23%LCAPLionheart Acquisition Co. IIN/AInsider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%BHCBausch Health Companies8.05%HRMYHarmony Biosciences23.60%LCAPLionheart Acquisition Co. II19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.10 million120.68 millionOptionableBHCBausch Health Companies19,900370.08 million338.06 millionOptionableHRMYHarmony Biosciences20057.42 million39.47 millionOptionableLCAPLionheart Acquisition Co. II318.45 million14.87 millionNot OptionableLCAP, ARWR, HRMY, and BHC HeadlinesRecent News About These CompaniesRF Acquisition Corp IISeptember 13, 2024 | morningstar.comLionheart Holdings - Ordinary Shares - Class AAugust 13, 2024 | money.usnews.comLionheart Capital Plans $1B Lakeside Mall Redevelopment in Sterling Heights, MichiganMay 2, 2024 | rebusinessonline.comMount Logan Capital Inc. Announces Entry into Business Combination With Canaccord Genuity G Ventures Corp.August 14, 2023 | markets.businessinsider.comMarwyn Acquisition Co. II Names Will Self as New CEOJune 6, 2023 | marketwatch.comLF Capital Acquisition Corp. II Provides Update Regarding Potential Business CombinationJune 2, 2023 | technews.tmcnet.comFrance Receives $47M in Funding From LVMH and Acquires Caillebotte PaintingJanuary 31, 2023 | news.yahoo.comPeraton Subsidiary Books $343M TSA Contract for IT Support; John Coleman QuotedDecember 21, 2022 | executivegov.comRevolution Healthcare Acquisition Corp. Will Redeem Public SharesNovember 28, 2022 | yahoo.comAcasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 12, 2022 | finance.yahoo.comMSP RECOVERY INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at MSP Recovery Inc.June 2, 2022 | apnews.comMSP Recovery shares plunge 64% following merger with SPAC LionheartMay 24, 2022 | seekingalpha.comSPAC Lionheart Acquisition Corp. II shareholders approve MSP Recovery mergerMay 19, 2022 | seekingalpha.comLionheart Acquisition Corporation II Shareholders Approve Previously Announced Business Combination with MSP RecoveryMay 18, 2022 | finance.yahoo.comCEO defends $800,000 NIL deal with college athlete: ‘We're going to be on everybody's minds'May 17, 2022 | finance.yahoo.comMSP Recovery Sees Substantial Business Expansion Since Announcement of Its Business Combination Through Development of Additional Revenue Streams, MonMay 17, 2022 | us.acrofan.comMSP Recovery Sees Substantial Business Expansion Since AnnouncementMay 17, 2022 | tmcnet.comMSP Recovery Sees Substantial Business Expansion Since Announcement of Its Business Combination Through Development of Additional Revenue Streams, Monetization of Assignor Interests, Growth of Existing Business, and Continued InnovationMay 17, 2022 | finance.yahoo.comLionheart Acquisition Corporation II Enters into Non-Binding Term Sheets for Forward Purchase Agreement and Committed Equity Facility with Cantor Fitzgerald L.P.May 13, 2022 | finance.yahoo.comSPAC Lionheart gets 6 months extension to complete deal with MSP RecoveryJanuary 31, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCAP, ARWR, HRMY, and BHC Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$17.17 +0.20 (+1.18%) As of 10:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Bausch Health Companies NYSE:BHC$5.04 -0.06 (-1.08%) As of 10:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Harmony Biosciences NASDAQ:HRMY$36.08 +0.24 (+0.66%) As of 10:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Lionheart Acquisition Co. II NASDAQ:LCAPLionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects D-Wave Is Soaring—But Is ETF Diversification the Better Strategy? Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
